Investment Rating - The report assigns a "Buy" rating for the company, expecting a future investment return of 5% to 15% over the next six months [4]. Core Insights - The company achieved a revenue of 3.03 billion RMB in 2024, representing a year-on-year growth of 5.4%, while the net profit attributable to shareholders was 1.96 billion RMB, also up by 5.3% year-on-year [2][5]. - In Q4, the company experienced a revenue decline of 7.0% year-on-year and a net profit decrease of 15.5% year-on-year, which was slightly below market expectations [2][4]. - The company is increasing its R&D efforts, with a research and development expense ratio of 10.0% in 2024, up by 1.3 percentage points from the previous year [3]. Financial Performance Summary - For 2024, the company reported a gross margin of 94.6%, a slight decrease of 0.5 percentage points compared to the same period in 2023, while the net profit margin remained stable at 64.7% [2][5]. - The company plans to distribute a total cash dividend of 1.15 billion RMB to shareholders, which accounts for 58.5% of the net profit attributable to shareholders [2]. - The projected net profits for 2025, 2026, and 2027 are estimated to be 2.09 billion RMB, 2.34 billion RMB, and 2.59 billion RMB, respectively, with corresponding growth rates of 6.8%, 12.0%, and 10.6% [4][5]. Strategic Developments - The company is making strides towards internationalization by acquiring 85% of the Korean company REGEN Biotech for 190 million USD, which is expected to enhance future performance [4]. - The company has several products in the registration and clinical trial stages, including A-type botulinum toxin and minoxidil topical solution, indicating a strong pipeline for future growth [3].

Investment Rating - The report maintains a "Recommendation" rating for the company, indicating an expectation that the stock will outperform the market by 10% to 20% over the next six months [1][13]. Core Views - Despite macroeconomic impacts, the company's performance remains robust, with a projected revenue of 30.26 billion yuan in 2024, reflecting a year-on-year growth of 5.45%. The net profit is expected to grow by 5.33% to 19.58 billion yuan [1][3]. - The company is focusing on expanding its product line and has made significant progress in its product pipeline, including the approval of several medical devices and clinical trial applications [1][5]. - The company is enhancing its operational capabilities through digital platform development and supply chain improvements, which are expected to drive future growth [1][11]. Financial Summary - In 2024, the company anticipates a revenue of 30.26 billion yuan, with a net profit of 19.58 billion yuan, and a basic EPS of 6.5 yuan. The cash flow from operating activities is projected to be 19.27 billion yuan [1][4]. - The company reported a decline in Q4 revenue by 7% to 6.5 billion yuan, with a net profit decrease of 15.47% to 3.72 billion yuan. The gross margin for the quarter was 94.03%, and the net margin was 57.09% [4][9]. - The company’s financial projections for 2025 estimate revenues of 34.79 billion yuan and net profits of 22.09 billion yuan, with a corresponding P/E ratio of 26.6 [6][12].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [4][12]. Core Insights - In 2024, the company achieved revenue of 3.026 billion RMB, a year-on-year increase of 5.5%, and a net profit attributable to shareholders of 1.958 billion RMB, up 5.3% year-on-year [1]. - The company is experiencing a mixed performance in its product lines, with injection gel and solution products showing growth despite a weak overall market demand in the medical aesthetics sector [2]. - The company has made significant progress in its product pipeline, with multiple research and development projects advancing, which lays a foundation for future growth [3]. Financial Performance - The company reported a revenue of 30.26 billion RMB in 2024, with a net profit of 19.58 billion RMB, and a non-recurring net profit of 18.72 billion RMB [1]. - For the fourth quarter of 2024, the company recorded a revenue of 6.5 billion RMB, a decrease of 7% year-on-year, and a net profit of 3.72 billion RMB, down 15.5% year-on-year [1]. - The revenue from solution injection products was 17.44 billion RMB, growing by 4.4% year-on-year, while gel injection products generated 12.16 billion RMB, up 5.01% year-on-year [2]. Profit Forecast and Valuation - The profit forecast for 2025-2027 estimates net profits of 2.381 billion RMB, 2.874 billion RMB, and 3.368 billion RMB, representing year-on-year growth rates of 22%, 21%, and 17% respectively [4]. - The earnings per share (EPS) for the same period are projected to be 7.87 RMB, 9.50 RMB, and 11.13 RMB, with corresponding price-to-earnings (P/E) ratios of 24, 20, and 17 [4].

Investment Rating - The report maintains a "Recommended" rating for the company [4][6][10]. Core Insights - The company achieved a revenue of 3.026 billion yuan in 2024, representing a year-on-year growth of 5.45%, and a net profit attributable to shareholders of 1.958 billion yuan, up 5.33% year-on-year [1][4]. - The acquisition of REGEN Biotech for 190 million USD is a strategic move to enhance the company's competitive edge and international presence in the aesthetic medicine market [2][3]. - The company has a robust pipeline of products, with several expected to launch soon, indicating strong growth potential in the medium to long term [3][4]. Financial Performance Summary - **Revenue and Profit Forecasts**: - 2024 Revenue: 3.026 billion yuan, 2025 Revenue: 3.390 billion yuan (12.0% growth), 2026 Revenue: 3.911 billion yuan (15.4% growth), 2027 Revenue: 4.777 billion yuan (22.1% growth) [4][6]. - 2024 Net Profit: 1.958 billion yuan, 2025 Net Profit: 2.198 billion yuan (12.3% growth), 2026 Net Profit: 2.567 billion yuan (16.8% growth), 2027 Net Profit: 3.168 billion yuan (23.4% growth) [4][6]. - **Valuation Metrics**: - PE ratios for 2025, 2026, and 2027 are projected at 26X, 22X, and 18X respectively [4][6]. - The company’s net profit margin for 2024 is 64.66%, with a slight increase expected in subsequent years [1][6].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the benchmark index [4][7]. Core Insights - The company reported a slight increase in annual revenue and profit, with a total revenue of 3.026 billion yuan, up 5.45% year-on-year, and a net profit attributable to the parent company of 1.958 billion yuan, up 5.33% year-on-year [1]. - The gross margin was 94.64%, a decrease of 0.46 percentage points year-on-year, while the net profit margin slightly increased to 64.66% [1]. - The company is actively expanding its product lines through mergers and acquisitions, including a recent acquisition of an 85% stake in a Korean company to enhance its product pipeline and international presence [3]. Financial Performance Summary - In Q4, the company experienced a decline in revenue and net profit, with a decrease of 7.00% and 15.47% respectively [1]. - The R&D expense ratio increased to 10.04%, reflecting a 1.32 percentage point rise year-on-year, indicating a commitment to innovation [1]. - The company plans to distribute a cash dividend of 38 yuan for every 10 shares, resulting in a dividend payout ratio of 58.51% [1]. Product Category Performance - Revenue from solution-type injection products reached 1.744 billion yuan, a year-on-year increase of 4.40%, with sales volume growing by 23.44% [2]. - Gel-type injection products generated 1.216 billion yuan in revenue, up 5.01% year-on-year, although sales volume decreased by 11.24% [2]. Research and Development Pipeline - The company has a rich pipeline of products under development, including several medical devices and drugs that have received regulatory approvals for clinical trials [3]. - The establishment of a joint venture in Hong Kong aims to facilitate further acquisitions and enhance the company's product offerings in the regenerative aesthetic market [3]. Earnings Forecast - The company is projected to achieve earnings per share (EPS) of 7.55, 8.45, and 9.26 yuan for the years 2025, 2026, and 2027 respectively, with corresponding price-to-earnings (P/E) ratios of 26, 23, and 21 [4].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the benchmark index [4][7]. Core Insights - The company reported a slight increase in revenue and profit for the year 2024, with total revenue reaching 3.026 billion yuan, up 5.45% year-on-year, and net profit attributable to the parent company at 1.958 billion yuan, up 5.33% year-on-year [1][4]. - The company is actively expanding its product lines through mergers and acquisitions, enhancing its market position in the aesthetic medicine sector [3][4]. - The company plans to distribute a cash dividend of 38 yuan for every 10 shares, resulting in a dividend payout ratio of 58.51% [1]. Financial Performance Summary - In Q4 2024, the company experienced a decline in revenue and net profit, with revenue down 7.00% and net profit down 15.47% compared to the previous year [1]. - The gross profit margin for 2024 was 94.64%, a decrease of 0.46 percentage points year-on-year, while the net profit margin slightly increased to 64.66% [1]. - The company’s R&D expenses increased to 10.04% of revenue, reflecting a 1.32 percentage point rise year-on-year [1]. Product Category Performance - Revenue from solution-type injection products was 1.744 billion yuan, a year-on-year increase of 4.40%, with sales volume rising by 23.44% [2]. - Revenue from gel-type injection products reached 1.216 billion yuan, up 5.01% year-on-year, although sales volume decreased by 11.24% [2]. Research and Development Pipeline - The company has a rich pipeline of products under development, including several that have received clinical trial approvals and registration certificates [3]. - A significant acquisition is planned, with the company aiming to acquire 85% of the Korean REGEN Biotech, which is expected to enhance its product offerings in regenerative aesthetic medicine [3]. Earnings Forecast - The company is projected to achieve earnings per share (EPS) of 7.55 yuan, 8.45 yuan, and 9.26 yuan for the years 2025, 2026, and 2027, respectively [4][6].

Investment Rating - The report maintains a "Buy" rating for the company [5][8]. Core Insights - The company reported a revenue of 3.03 billion yuan for 2024, reflecting a year-on-year growth of 5.4%, while the net profit attributable to shareholders was 1.96 billion yuan, also up by 5.3% [5][8]. - The fourth quarter of 2024 saw a decline in revenue to 650 million yuan, down 7.0% year-on-year, and a net profit of 370 million yuan, down 15.5% year-on-year [5][8]. - The company plans to distribute a cash dividend of 38 yuan for every 10 shares to all shareholders [5]. Summary by Sections Financial Performance - Revenue from solution products and gel products for 2024 was 1.74 billion yuan and 1.22 billion yuan, respectively, with year-on-year growth of 4.4% and 5.0% [6]. - The sales volume for solution products was 634.6 thousand units, up 23.4%, while gel products saw a decline in sales volume by 11.2% to 89.4 thousand units [6]. - The overall gross margin for the company decreased by 0.5 percentage points to 94.6%, while the net profit margin decreased by 0.1 percentage points to 64.7% [6][8]. R&D and Product Development - The company increased its R&D investment, completing 57 patent applications and engaging in 21 research projects with various medical institutions [7]. - New products are expected to enhance the gel product line, including a medical gel for chin augmentation and other injectable products that have received clinical trial approvals [7][8]. M&A and Market Expansion - The company plans to acquire AestheFill's source company, REGEN Biotech, Inc., which is expected to enhance its competitive advantage in the global regenerative market and strengthen its overseas market expansion capabilities [8]. - The report anticipates that the combination of mergers and acquisitions along with overseas expansion will provide new growth points for the company [8]. Financial Projections - Revenue projections for 2025 and 2026 have been adjusted to 3.213 billion yuan and 3.837 billion yuan, reflecting downward revisions of 15% and 17% respectively [8]. - The expected net profit for 2025 and 2026 is projected to be 2.062 billion yuan and 2.448 billion yuan, also down by 15% for both years [8]. - The report introduces a new revenue and net profit forecast for 2027 at 4.425 billion yuan and 2.814 billion yuan, respectively [8].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 202.76 CNY [3][6]. Core Views - The company faces short-term challenges but is expected to achieve long-term growth through both internal and external initiatives [1][6]. - The profit forecast has been adjusted, with expected net profits for 2025-2027 being 2.166 billion, 2.452 billion, and 2.817 billion CNY respectively [2][6]. Financial Performance Summary - **Revenue**: - 2023A: 2,869 million CNY, 2024A: 3,026 million CNY, 2025E: 3,411 million CNY, 2026E: 3,952 million CNY, 2027E: 4,639 million CNY - Year-on-year growth: 48.0% in 2023, 5.4% in 2024, 12.8% in 2025, 15.8% in 2026, and 17.4% in 2027 [2][11]. - **Net Profit**: - 2023A: 1,858 million CNY, 2024A: 1,958 million CNY, 2025E: 2,166 million CNY, 2026E: 2,452 million CNY, 2027E: 2,817 million CNY - Year-on-year growth: 47.1% in 2023, 5.3% in 2024, 10.6% in 2025, 13.2% in 2026, and 14.9% in 2027 [2][11]. - **Gross Margin**: - 2023A: 95.1%, 2024A: 94.6%, 2025E: 93.2%, 2026E: 91.2%, 2027E: 88.7% [2][11]. - **Net Margin**: - 2023A: 64.8%, 2024A: 64.7%, 2025E: 63.5%, 2026E: 62.1%, 2027E: 60.7% [2][11]. - **Return on Equity (ROE)**: - 2023A: 30.5%, 2024A: 27.7%, 2025E: 23.8%, 2026E: 22.4%, 2027E: 23.1% [2][11]. Strategic Developments - The company is expanding its product pipeline, including new products aimed at various medical applications, which are expected to launch in the second half of 2025 [5][6]. - The acquisition of REGEN Biotech is part of the company's strategy to accelerate international expansion, with a purchase price of 190 million USD for 85% of the company [5][6].

核心观点 爱美客 300896.SZ 公司研究 | 年报点评 短期有挑战，内生+外延并举推动中长期增 长 盈利预测与投资建议 ⚫ 根据年报，暂不考虑收购带来的效益，同时考虑消费复苏的波动性，我们调整盈利 预测并引入 2027 年的盈利预测，预计公司 2025-2027 年归母净利润为 21.66 亿、 24.52 亿和 28.17 亿（原 25-26 年为 24.89 亿和 30.3 亿），DCF 目标估值 202.76 元，维持"买入"评级。 风险提示：行业竞争加剧、终端消费需求持续减弱、储备管线拿证上市及拓展不及预 期 公司主要财务信息 | | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 2,869 | 3,026 | 3,411 | 3,952 | 4,639 | | 同比增长 (%) | 48.0% | 5.4% | 12.8% | 15.8% | 17.4% | | 营业利润(百万元) | 2,158 | 2,291 | 2,526 | 2,859 | 3,28 ...

基础数据：2024 年 12 月 31 日 | 基本每股收益(元)： | 6.50 | | --- | --- | | 摊薄每股收益(元)： | 6.50 | | 每股净资产(元)： | 26.27 | | 净资产收益率(%)： | 24.61 | 资料来源：最闻 分析师： 医疗器械 爱美客（300896.SZ） 买入-B(维持) 在研产品储备丰富，外延收购加速国际化布局 2025 年 3 月 21 日 公司研究/公司快报 公司近一年市场表现 事件描述 | 市场数据：2025 3 | 年 月 | 日 21 | | | --- | --- | --- | --- | | 收盘价（元）： | | | 190.10 | | 年内最高/最低（元）： | | | 350.99/132.81 | | 流通 A | 股/总股本（亿股）： | | 2.09/3.03 | | 流通 A | 股市值（亿元）： | | 396.53 | | 总市值（亿元）： | | | 575.23 | 执业登记编码：S0760522030003 邮箱：wangfeng@sxzq.com 张晓霖 执业登记编码：S0760521010001 邮箱： ...